COSCIENS Biopharma announces the appointment of Pierre Labbé as Director

(MENAFN – GlobeNewsWire – Nasdaq) TORONTO, ONTARIO, Oct. 1, 2024 (GLOBE NEWSWIRE) — COSCIENS Biopharma Inc. (NASDAQ: CSCI) (TSX: CSCI) (“COSCIENS” or the “Company”), a specialty biopharmaceutical company developing and commercializing a diverse portfolio of cosmetic, nutraceutical and pharmaceutical products, announced the appointment of Pierre Labbé to its Board of Directors and as Chairman of its Audit Committee Company, effective today, to fill the vacancy created by the resignation of Dennis Turpin, also effective today.

Mr. Labbé has over 30 years of experience in management positions in various industries. Mr. Labbé is currently Executive Vice President of Finance at Fonds QScale SEC, which actively develops environmentally responsible computing centers, where he oversees financial strategy, investor relations, financial reporting, tax, treasury and risk management. Prior to joining Fonds QScale SEC, Mr. Labbé was CFO of IMV Inc. for five years. Previously, he served as CFO and Corporate Secretary of LeddarTech Inc., among others. and Medicago Inc. (TSX). Additionally, Mr. Labbé has been a director of Osisko Gold Royalties Ltd., a TSX and NYSE listed precious metals licensing company, since 2015 and currently serves as Chair of its Human Resources Committee and a member of its Audit Team and Risk Committee . As Senior CFO, Pierre played a key role in financings and mergers and acquisitions, overseeing transactions in excess of $1 billion.

“I am pleased to welcome Pierre to the COSCIENS board,” said Ronald Miller, CEO. “His track record of results-driven leadership, strategic thinking and financial acumen will be an asset as COSCIENS continues to pursue its strategic direction and achieve our goals. I would also like to express our gratitude to Mr. Dennis Turpin for his many years of dedicated service and, in particular, for sharing his financial expertise with the board over the years.”

Mr. Labbé holds a bachelor’s degree in business administration and a license in accounting from Université Laval in Québec City. He is a member of the Chartered Professional Accountants of Canada, the Quebec Chartered Professional Accountants Order and the Institute of Corporate Directors. It also has the ICD.D designation of the Institute of Corporate Directors.

About COSCIENS Biopharma Inc.

COSCIENS is a specialty biopharmaceutical company engaged in the development and commercialization of a diversified portfolio of pharmaceutical and diagnostic products, including products focused on areas of significant unmet medical need. One of COSCIENS’ leading products is macimorelin (Macrilen ® ; Grywelin ® ), the first and only oral test approved by the US FDA and the European Medicines Agency for the diagnosis of adult growth hormone deficiency (“AGHD”). COSCIENS is also committed to the development of therapeutic assets and proprietary extraction technology that is used to produce active ingredients from renewable plant resources currently used in cosmeceutical products (i.e. oat beta glucan and avenanthramide, which can be found in leading skin care brands, such as Aveeno and Burt’s Bees) and are being developed as potential nutraceuticals and/or pharmaceuticals.

The company is listed on the NASDAQ Capital Market and the Toronto Stock Exchange, and its shares are traded on both exchanges under the symbol “CSCI”. More information can be found on the COSCIENS website at .

Forward-Looking Statements

The information contained in this press release is made as of October 1, 2024. Certain statements contained in this press release, referred to herein as “forward-looking statements”, constitute “forward-looking statements” within the meaning of the Private Securities Act Litigation Reform Act Court Act 1995, as amended, and “forward-looking information” under Canadian securities laws. All statements, other than statements of historical fact, that address circumstances, events, actions or changes that may, may or will occur are forward-looking statements. Words such as “anticipate”, “assume”, “believe”, “may”, “expect”, “forecast”, “future”, “goal”, “guidance”, “intend” used in this press release “likely ”, “may”, “would” or negative or comparable terminology, and the terms commonly used in the future and condition are generally intended to identify forward-looking statements, although not all forward-looking statements contain such words.

Forward-looking statements are necessarily based on a number of factors and assumptions that, while considered reasonable by the Company as of the date such statements are made, are inherently subject to significant business, economic, operational and other risks, uncertainties, contingencies and other factors, including including those described below, which could cause the actual results, performance or achievements of the combined Company to be materially different from the results, performance or achievements expressed or implied by such forward-looking statements and, accordingly, undue reliance should not be placed on them.

Forward-looking statements involve known and unknown risks and uncertainties, including, but not limited to: the combined Company’s current and future business strategies; operations and results within expected ranges; expected future cash flows; local and global economic conditions and the environment in which the combined Company operates; expected capital and operating costs; uncertainties in our ability to generate revenues from our marketed products, product development and related clinical trials and validation studies; the results of products we develop may not be successful or may not support product improvements; the failure of the DETECT trial to meet its primary endpoint of growth hormone deficiency in children may impact the macimorelin (Macrilen) market ® ; Grywelin ® ) in AGHD and the existing relationships we have for this product; the ability to obtain capital and obtain financing to continue currently planned activities; our current heavy dependence on sales and revenues from our primary distributor of our legacy products, Ceapro, and its customers, the continued availability of funds and resources necessary to successfully commercialize our products; the ability to acquire strategic partners for late-stage development, marketing and distribution of our products; our ability to enter into and maintain outlicense, development, manufacturing, marketing and distribution agreements with other pharmaceutical companies; our ability to protect and enforce our portfolio of patents and intellectual property; and our ability to continue to list our common stock on the NASDAQ Capital Market.

Investors should refer to our quarterly and annual filings with the Canadian and U.S. Securities Exchange Commissions for additional information on risks and uncertainties, including those discussed in our Annual Report on Form 20-F and the MD&A filed as part of the Company’s profile on SEDAR+ and EDGAR websites at . We disclaim any obligation to update any such risks or uncertainties or to publicly announce any changes to any forward-looking statements contained herein to reflect future results, events or developments, except as required by any governmental authority or applicable law.

No securities regulatory authority has approved or disapproved the contents of this press release. The Toronto Stock Exchange disclaims any responsibility for the adequacy or accuracy of this press release.

Issuer:
Gilles R. Gagnon
President and CEO
…
+1 (780) 421-4555

Investor contact:
Jane Thomas
JTC Team
T (US): +1 (908) 824-0775
E: …

MENAFN01102024004107003653ID1108736940

Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We are not responsible for the accuracy, content, images, videos, licenses, completeness, legality or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, please contact the provider above.